Clinical Protocol and Data Management Core
Clinical Protocol and Data Management Core
批准号:
9209824
负责人:
DANIEL M SULLIVAN
金额:
$24.94万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AccountabilityAddressAdherenceAdverse eventBudgetsCancer CenterCancer Center Support GrantCaringClinicClinicalClinical Cancer CenterClinical DataClinical InvestigatorClinical ProtocolsClinical ResearchClinical SciencesClinical TrialsCommunicationCommunity OutreachCommunity RelationsConduct Clinical TrialsConsentContractsDataData CollectionData QualityData ReportingDevelopmentDevelopment PlansDrug KineticsEducationEducation and OutreachEducational CurriculumEducational workshopEligibility DeterminationEnrollmentEnsureFacultyGoalsHuman ResourcesIndividualIndustryInformed ConsentInsuranceIntervention TrialInvestigational TherapiesLeadLinguisticsLinkMinorityMonitorNational Clinical Trials NetworkPatient CarePatientsPerformancePharmaceutical PreparationsPharmacodynamicsPhysiciansPoliciesPositioning AttributePreparationPreventionProceduresProcessProtocols documentationReportingResearchResearch PersonnelResourcesSafetySamplingScienceServicesSiteStaff Work LoadStructureSupportive careSystemTherapeuticTherapeutic Clinical TrialTimeTrainingTraining and EducationTranslational ResearchTransportationUnderserved PopulationUpdateWomanWorkWorkloadbasedata managementflexibilityhealth disparityhigh standardinnovationmeetingsmemberminority healthmultidisciplinaryoutreachpoint of careprogramsprotocol developmentquality assuranceresearch studytrendtrial design
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Clinical Protocol & Data Management
PROJECT SUMMARY
Clinical Protocol & Data Management (CPDM) functions at Moffitt Cancer Center (MCC) include 1) trial design,
development, and conduct; 2) oversight of safety and compliance; 3) ensuring data quality and education of
personnel; and 4) appropriate accrual of women and minorities. A collaborative team of approximately 190
CPDM professionals provides centralized management and support of all types of clinical trials, including
investigator-initiated (IITs), industry or other sponsor-initiated, Experimental Therapeutics Clinical Trials
Network (ET-CTN), and National Clinical Trials Network (NCTN). CPDM support for members includes:
protocol development; budget development and contracting; regulatory and IND/IDE management; protocol
activation; patient enrollment; coordination of study-related patient care; research drug administration and care
services; correlative science (pharmacokinetics/pharmacodynamics) sample coordination; data collection and
reporting; monitoring of IIT studies and data and safety monitoring through the Protocol Monitoring Committee
(PMC) and Data Safety & Monitoring (DSM) Committee; audit preparation and coordination; minority outreach
and navigation for accrual to clinical trials; clinical trials management system (CTMS, OnCore) administration
and reporting; staff workload management; and staff education and training.
During the review period (FY2011-2015), the CPDM team successfully accrued and coordinated a combined
total of 11,851 patients to clinical interventional trials (therapeutic, prevention, and supportive care), including
accrual at affiliate sites.
CPDM provides centralized safety and compliance oversight to members through timely monitoring of
investigator-initiated interventional trials, coordination of the PMC, and corporate compliance audits of MCC
clinical research trials, policies, and processes. Results of monitoring and audits are utilized by the PMC for
comprehensive review.
MCC has developed and maintains proactive efforts to provide programs and services to women, minorities,
and other underserved populations through culturally and linguistically relevant care, education, and internal
and community outreach. Faculty members conduct research on minority health disparities, informing these
programs and services. In addition, the ACD for Clinical Science and the VP of Diversity and Community
Relations co-lead a multi-disciplinary Minority Clinical Research Committee to address issues related to
minority accrual at MCC. CPDM resources are closely integrated in these efforts.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS
-
批准号:8861643
-
项目类别:
-
资助金额:$41.38万
-
财政年份:2015
-
负责人:DANIEL M SULLIVAN
-
依托单位:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:8740463
-
项目类别:
-
资助金额:$36.76万
-
财政年份:2011
-
负责人:DANIEL M SULLIVAN
-
依托单位:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:8544374
-
项目类别:
-
资助金额:$73.51万
-
财政年份:2011
-
负责人:DANIEL M SULLIVAN
-
依托单位:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:9122264
-
项目类别:
-
资助金额:$12.48万
-
财政年份:2011
-
负责人:DANIEL M SULLIVAN
-
依托单位:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:8352532
-
项目类别:
-
资助金额:$66.16万
-
财政年份:2011
-
负责人:DANIEL M SULLIVAN
-
依托单位:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:8919809
-
项目类别:
-
资助金额:$49.01万
-
财政年份:2011
-
负责人:DANIEL M SULLIVAN
-
依托单位:
Early Therapuetics with Phase II Emphasis
-
批准号:8014375
-
项目类别:
-
资助金额:$124.79万
-
财政年份:2006
-
负责人:DANIEL M SULLIVAN
-
依托单位:
Early Therapuetics with Phase II Emphasis
-
批准号:8257118
-
项目类别:
-
资助金额:$63.93万
-
财政年份:2006
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DRUG SEQUENCING RESISTANCE IN MULTIPLE MYELOMA
-
批准号:2875944
-
项目类别:
-
资助金额:$14.11万
-
财政年份:1999
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DRUG RESISTANCE TO INHIBITORS OF DNA TOPOISOMERASE II
-
批准号:2100358
-
项目类别:
-
资助金额:$16.63万
-
财政年份:1994
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DRUG RESISTANCE TO INHIBITORS OF DNA TOPOISOMERASE II
-
批准号:2429778
-
项目类别:
-
资助金额:$18.22万
-
财政年份:1994
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DRUG RESISTANCE TO INHIBITORS OF DNA TOPOISOMERASE II
-
批准号:2100359
-
项目类别:
-
资助金额:$27.05万
-
财政年份:1994
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DRUG RESISTANCE TO INHIBITORS OF DNA TOPOISOMERASE II
-
批准号:2100360
-
项目类别:
-
资助金额:$17.52万
-
财政年份:1994
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DNA TOPOISOMERASE ACTIVITY AND CANCER THERAPY
-
批准号:3079629
-
项目类别:
-
资助金额:$6.31万
-
财政年份:1987
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DNA TOPOISOMERASE ACTIVITY AND CANCER THERAPY
-
批准号:3079632
-
项目类别:
-
资助金额:$1.01万
-
财政年份:1987
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DNA TOPOISOMERASE ACTIVITY AND CANCER THERAPY
-
批准号:3079628
-
项目类别:
-
资助金额:$8.36万
-
财政年份:1987
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DNA TOPOISOMERASE ACTIVITY AND CANCER THERAPY
-
批准号:3079631
-
项目类别:
-
资助金额:$8.49万
-
财政年份:1987
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DNA TOPOISOMERASE ACTIVITY AND CANCER THERAPY
-
批准号:3079630
-
项目类别:
-
资助金额:$6.96万
-
财政年份:1987
-
负责人:DANIEL M SULLIVAN
-
依托单位:
DNA TOPOISOMERASE ACTIVITY AND CANCER THERAPY
-
批准号:3079627
-
项目类别:
-
资助金额:$3.23万
-
财政年份:1987
-
负责人:DANIEL M SULLIVAN
-
依托单位:
CLINICAL TRIALS OFFICE
-
批准号:8491592
-
项目类别:
-
资助金额:$29.95万
-
财政年份:--
-
负责人:DANIEL M SULLIVAN
-
依托单位:
海外基金